Literature DB >> 8797709

The HTLV-I envelope glycoproteins: structure and functions.

L Delamarre1, A R Rosenberg, C Pique, D Pham, I Callebaut, M C Dokhélar.   

Abstract

The human T-cell lymphotropic virus type I (HTLV-I) envelope has a structural organization shared by all retroviral envelopes, which contain two mature viral glycoproteins deriving from a common precursor: an external surface protein (SU), associated with a transmembrane protein (TM) responsible for anchoring the SU-TM complex at the cell surface or in the viral envelope. Our understanding of the tertiary structure of these proteins is extremely poor. The intracellular maturation follows the normal cellular secretory pathway, resulting in expression of the mature glycoproteins at the cell surface. The five potential N-glycosylation sites are glycosylated. Most mutations artificially introduced into the glycoproteins result in loss of function, mostly due to abnormal intracellular maturation. This probably indicates a very compact structure of these proteins, where the entire structure is involved in correct conformation. Studies using neutralizing antibodies or mutagenesis have defined functional domains in the SU protein, which is responsible for receptor binding. These domains occur throughout the SU glycoprotein. Sequence analysis of the HTLV-I TM predicts a structure, and probably functions, similar to other retrovirus TMs: involvement of this glycoprotein in the different oligomerization steps leading to a fusogenic SU-TM complex and in the fusion process itself. These features remain to be proven, and it is not yet understood why the free HTLV-I viral particle is not infectious.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8797709     DOI: 10.1097/00042560-199600001-00015

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  19 in total

1.  The ectodomain of the human T-cell leukemia virus type 1 TM glycoprotein is involved in postfusion events.

Authors:  A R Rosenberg; L Delamarre; C Pique; D Pham; M C Dokhélar
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  In vivo analysis of replication and immunogenicity of proviral clones of human T-lymphotropic virus type 1 with selective envelope surface-unit mutations.

Authors:  Lee R Silverman; Andrew J Phipps; Andy Montgomery; Soledad Fernandez; Tomonori Tsukahara; Lee Ratner; Michael D Lairmore
Journal:  Blood       Date:  2005-07-26       Impact factor: 22.113

3.  Cross-reactive antibodies to target proteins are dependent upon oligomannose glycosylated epitopes in HTLV-1 associated neurological disease.

Authors:  Sangmin Lee; Yoojin Shin; Daniel Clark; Eduardo Gotuzzo; Michael C Levin
Journal:  J Clin Immunol       Date:  2012-03-06       Impact factor: 8.317

4.  Opposing effects of a tyrosine-based sorting motif and a PDZ-binding motif regulate human T-lymphotropic virus type 1 envelope trafficking.

Authors:  Anna Ilinskaya; Gisela Heidecker; David Derse
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

5.  Characterization of envelope glycoprotein mutants for human T-cell leukemia virus type 1 infectivity and immortalization.

Authors:  T Tsukahara; M M Wielgosz; L Ratner
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Inhibition of cell-free human T-cell leukemia virus type 1 infection at a postbinding step by the synthetic peptide derived from an ectodomain of the gp21 transmembrane glycoprotein.

Authors:  A Jinno; Y Haraguchi; H Shiraki; H Hoshino
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

7.  Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin.

Authors:  Kazu Okuma; Kevin P Dalton; Linda Buonocore; Elizabeth Ramsburg; John K Rose
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Crystallization of a trimeric human T cell leukemia virus type 1 gp21 ectodomain fragment as a chimera with maltose-binding protein.

Authors:  R J Center; B Kobe; K A Wilson; T Teh; G J Howlett; B E Kemp; P Poumbourios
Journal:  Protein Sci       Date:  1998-07       Impact factor: 6.725

9.  Syncytium-inhibiting monoclonal antibodies produced against human T-cell lymphotropic virus type 1-infected cells recognize class II major histocompatibility complex molecules and block by protein crowding.

Authors:  J E Hildreth
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

Review 10.  Current concepts regarding the HTLV-1 receptor complex.

Authors:  David Ghez; Yves Lepelletier; Kathryn S Jones; Claudine Pique; Olivier Hermine
Journal:  Retrovirology       Date:  2010-11-29       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.